Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Jul;26(7):783-90.
doi: 10.1007/s11606-010-1629-x. Epub 2011 Feb 1.

Examining the evidence: a systematic review of the inclusion and analysis of older adults in randomized controlled trials

Affiliations

Examining the evidence: a systematic review of the inclusion and analysis of older adults in randomized controlled trials

Donna M Zulman et al. J Gen Intern Med. 2011 Jul.

Abstract

Background: Due to a shortage of studies focusing on older adults, clinicians and policy makers frequently rely on clinical trials of the general population to provide supportive evidence for treating complex, older patients.

Objectives: To examine the inclusion and analysis of complex, older adults in randomized controlled trials.

Review methods: A PubMed search identified phase III or IV randomized controlled trials published in 2007 in JAMA, NEJM, Lancet, Circulation, and BMJ. Therapeutic interventions that assessed major morbidity or mortality in adults were included. For each study, age eligibility, average age of study population, primary and secondary outcomes, exclusion criteria, and the frequency, characteristics, and methodology of age-specific subgroup analyses were reviewed.

Results: Of the 109 clinical trials reviewed in full, 22 (20.2%) excluded patients above a specified age. Almost half (45.6%) of the remaining trials excluded individuals using criteria that could disproportionately impact older adults. Only one in four trials (26.6%) examined outcomes that are considered highly relevant to older adults, such as health status or quality of life. Of the 42 (38.5%) trials that performed an age-specific subgroup analysis, fewer than half examined potential confounders of differential treatment effects by age, such as comorbidities or risk of primary outcome. Trials with age-specific subgroup analyses were more likely than those without to be multicenter trials (97.6% vs. 79.1%, p < 0.01) and funded by industry (83.3% vs. 62.7%, p < 0.05). Differential benefit by age was found in seven trials (16.7%).

Conclusion: Clinical trial evidence guiding treatment of complex, older adults could be improved by eliminating upper age limits for study inclusion, by reducing the use of eligibility criteria that disproportionately affect multimorbid older patients, by evaluating outcomes that are highly relevant to older individuals, and by encouraging adherence to recommended analytic methods for evaluating differential treatment effects by age.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Study selection process.

Comment in

  • Inclusion and analysis of older adults in RCTs.
    Van de Water W, Bastiaannet E, Van de Velde CJ, Liefers GJ. Van de Water W, et al. J Gen Intern Med. 2011 Aug;26(8):831; author reply 832. doi: 10.1007/s11606-011-1705-x. J Gen Intern Med. 2011. PMID: 21503814 Free PMC article. No abstract available.

References

    1. Hartman M, Catlin A, Lassman D, Cylus J, Heffler S. US health spending by age, selected years through 2004. Health Aff (Millwood) 2008;27(1):w1–w12. doi: 10.1377/hlthaff.27.1.w1. - DOI - PubMed
    1. Machlin S. Trends in health care expenditures for the elderly age 65 and over: 2006 versus 1996. Statistical Brief #256. Rockville, MD. 2009.
    1. McMurdo MET, Witham MD, Gillespie ND. Including older people in clinical research—benefits shown in trials in younger people may not apply to older people. Br Med J. 2005;331(7524):1036–7. doi: 10.1136/bmj.331.7524.1036. - DOI - PMC - PubMed
    1. Besdine R, Boult C, Brangman S, et al. Caring for older Americans: the future of geriatric medicine. J Am Geriatr Soc. 2005;53(6 Suppl):S245–56. - PubMed
    1. The ACCORD Study Group. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010. - PMC - PubMed
References for Appendix Table
    1. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, O'Toole T, Lustgarten S, Moore L. Trial. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007;356(22):2271–81. doi: 10.1056/NEJMoa066838. - DOI - PubMed
    1. Konstam MA, Gheorghiade M, Burnett JC, Jr, Grinfeld L, Maggioni AP, Swedberg K, Udelson JE, Zannad F, Cook T, Ouyang J, Zimmer C, Orlandi C. Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA. 2007;297(12):1319–31. doi: 10.1001/jama.297.12.1319. - DOI - PubMed
    1. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, Shenkier T, Cella D, Davidson NE. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007;357(26):2666–76. doi: 10.1056/NEJMoa072113. - DOI - PubMed
    1. Quasar Collaborative Group. Gray R, Barnwell J, McConkey C, Hills RK, Williams NS, Kerr DJ. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet. 2007;370(9604):2020–9. doi: 10.1016/S0140-6736(07)61866-2. - DOI - PubMed
    1. Weinstein JN, Lurie JD, Tosteson TD, Hanscom B, Tosteson AN, Blood EA, Birkmeyer NJ, Hilibrand AS, Herkowitz H, Cammisa FP, Albert TJ, Emery SE, Lenke LG, Abdu WA, Longley M, Errico TJ, Hu SS. Surgical versus nonsurgical treatment for lumbar degenerative spondylolisthesis. N Engl J Med. 2007;356(22):2257–70. doi: 10.1056/NEJMoa070302. - DOI - PMC - PubMed

Publication types

LinkOut - more resources